[go: up one dir, main page]

BR0214674A - Derivados 4-piperdinil alquilamina como antagonistas do receptor muscarìnico - Google Patents

Derivados 4-piperdinil alquilamina como antagonistas do receptor muscarìnico

Info

Publication number
BR0214674A
BR0214674A BR0214674-6A BR0214674A BR0214674A BR 0214674 A BR0214674 A BR 0214674A BR 0214674 A BR0214674 A BR 0214674A BR 0214674 A BR0214674 A BR 0214674A
Authority
BR
Brazil
Prior art keywords
receptor antagonists
muscarinic receptor
piperdinyl
alkylamine derivatives
compounds
Prior art date
Application number
BR0214674-6A
Other languages
English (en)
Inventor
Christine E Brotherton-Pleiss
Ann Marie Madera
Robert James Weikert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0214674A publication Critical patent/BR0214674A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS 4-PIPERIDINIL ALQUILAMINA COMO ANTAGONISTAS DO RECEPTOR MUSCARìNICO". A presente invenção refere-se geralmente a compostos que são antagonsitas do receptor muscarínico, e que são representados pela fórmula geral (I) onde p, R^ 1^, R^ 2^, R^ 3^ e A são conforme indicados no relatório descritivo, ou os isómeros individuais, misturas racêmicas, ou não-racêmicas de isómeros, ou os sais ou solvatos aceitáveis destes. A invenção compreende ainda composições farmacêuticas contendo tais compostos processos para sua preparação e seu uso como agentes terapêuticos.
BR0214674-6A 2001-12-03 2002-11-25 Derivados 4-piperdinil alquilamina como antagonistas do receptor muscarìnico BR0214674A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33679501P 2001-12-03 2001-12-03
PCT/EP2002/013220 WO2003048124A1 (en) 2001-12-03 2002-11-25 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists

Publications (1)

Publication Number Publication Date
BR0214674A true BR0214674A (pt) 2004-10-19

Family

ID=23317699

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214674-6A BR0214674A (pt) 2001-12-03 2002-11-25 Derivados 4-piperdinil alquilamina como antagonistas do receptor muscarìnico

Country Status (15)

Country Link
US (2) US6627644B2 (pt)
EP (1) EP1453805B1 (pt)
JP (1) JP4353803B2 (pt)
KR (1) KR100687992B1 (pt)
CN (1) CN100352806C (pt)
AR (1) AR037612A1 (pt)
AT (1) ATE492535T1 (pt)
AU (1) AU2002352125A1 (pt)
BR (1) BR0214674A (pt)
CA (1) CA2468691C (pt)
DE (1) DE60238709D1 (pt)
MX (1) MXPA04005076A (pt)
PL (1) PL370765A1 (pt)
RU (1) RU2300524C2 (pt)
WO (1) WO2003048124A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048124A1 (en) * 2001-12-03 2003-06-12 F. Hoffmann-La Roche Ag 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists
BR0215801A (pt) 2002-07-08 2005-05-10 Ranbaxy Lab Ltd Derivados de 3,6-dissubstituìdos azabiciclo [3.1.0] hexano úteis como antagonistas de receptores muscarìnicos
TW200800953A (en) 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
US7488748B2 (en) * 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1626957A1 (en) 2003-04-11 2006-02-22 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
WO2005007645A1 (en) 2003-07-11 2005-01-27 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
US8039464B2 (en) 2004-07-16 2011-10-18 Proteosys Ag Muscarinic antagonists with PARP and SIR modulating activity as agents for inflammatory diseases
US20090105221A1 (en) * 2004-09-29 2009-04-23 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US20100016400A1 (en) * 2004-11-19 2010-01-21 Naresh Kumar Azabicyclic muscarinic receptor antagonists
US20100035954A1 (en) * 2004-12-15 2010-02-11 Mohammad Salman Acid addition salts of muscarinic receptor antagonists
EP1888525A1 (en) * 2005-05-03 2008-02-20 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives as muscarinic receptor antagonists
TW200944526A (en) 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
WO2010081825A2 (en) 2009-01-13 2010-07-22 Proteosys Ag Pirenzepine as an agent in cancer treatment
KR101034492B1 (ko) * 2009-05-27 2011-05-17 하태헌 철도 차량의 발전 장치

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3718317A1 (de) 1986-12-10 1988-06-16 Bayer Ag Substituierte basische 2-aminotetraline
CA1331191C (en) 1988-03-25 1994-08-02 Bengt Ronny Andersson Therapeutically useful tetralin derivatives
FR2659323B1 (fr) 1990-03-07 1992-06-12 Synthelabo Derives de 4-(aminomethyl) piperidine, leur preparation et leur application en therapeutique.
FR2659853A1 (fr) 1990-03-22 1991-09-27 Midy Spa Utilisation de derives 2-aminotetraliniques pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale.
US6319920B1 (en) 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
YU88902A (sh) 2000-05-25 2006-01-16 F. Hoffmann-La Roche Ag. Supstituisani 1-aminoalkil laktami i njihova primena kao antagonista muskarinskih receptora
ATE280162T1 (de) 2000-05-25 2004-11-15 Hoffmann La Roche Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
WO2003048124A1 (en) * 2001-12-03 2003-06-12 F. Hoffmann-La Roche Ag 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists

Also Published As

Publication number Publication date
RU2004120556A (ru) 2005-07-10
EP1453805B1 (en) 2010-12-22
CN100352806C (zh) 2007-12-05
US20040092554A1 (en) 2004-05-13
JP2005517641A (ja) 2005-06-16
PL370765A1 (en) 2005-05-30
ATE492535T1 (de) 2011-01-15
CA2468691A1 (en) 2003-06-12
KR20050044633A (ko) 2005-05-12
US6627644B2 (en) 2003-09-30
MXPA04005076A (es) 2004-08-19
RU2300524C2 (ru) 2007-06-10
KR100687992B1 (ko) 2007-02-27
JP4353803B2 (ja) 2009-10-28
EP1453805A1 (en) 2004-09-08
WO2003048124A1 (en) 2003-06-12
AR037612A1 (es) 2004-11-17
US6864266B2 (en) 2005-03-08
US20030162780A1 (en) 2003-08-28
DE60238709D1 (de) 2011-02-03
AU2002352125A1 (en) 2003-06-17
CA2468691C (en) 2011-03-08
CN1599722A (zh) 2005-03-23

Similar Documents

Publication Publication Date Title
BR0109235A (pt) Derivados do ácido carboxìlico como antagonistas ip
BR0307406A (pt) Indóis substituìdos como agonistas alfa-1
BR0316950A (pt) Derivados de indazol como antagonistas de crf
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
BR0214674A (pt) Derivados 4-piperdinil alquilamina como antagonistas do receptor muscarìnico
BR0116662A (pt) Derivados de quinazolona como antagonistas receptores alfa 1a/b adrenérgicos
BRPI0409986A (pt) derivados de pirimidina fundida com atividade de crf
BR0315317A (pt) 4-piperazinil benzenossulfonil indóis com afinidade para o receptor de 5-ht6
UY27336A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
BR0108679A (pt) Novos compostos
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
YU53100A (sh) Derivati 2-ariletil-(piperidin-4-ilmetil)amina kao antagonisti muskarinskih receptora
ECSP034744A (es) Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos
BR0312560A (pt) Novas espiropiperidinas ou espiropirrolidinas tricìclicas
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
UY25804A1 (es) Derivados de 4-aroilpiperidina que son antagonistas de los receptores ccr-3
BRPI0409241A (pt) compostos bicìclicos como antagonistas do receptor de nr2b, composições farmacêuticas compreendendo os mesmos e seu uso
BR0113585A (pt) Derivados quinazolina como antagonistas adrenérgicos alfa-1
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
BR0214649A (pt) Derivados de aminotetralina como antagonistas do receptor muscarìnico
NO20040589L (no) Arylsulfonylderivater med 5-HT6 reseptor affinitet.
BR0214695A (pt) Derivados de pirazol com anel fundido
BR0207795A (pt) Derivados de ácido alcoxicarbonilamino benzóico ou alcoxicarbonilamino tetrazolil fenila como antagonistas de ip
BR0207730A (pt) Derivados de ácido alcoxicarbonila-mino-heteroaril carboxìlico, como antagonistas de ip
BR9905974A (pt) Derivados de ácido aril carboxìlico e tetrazol

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.